

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA**

NOVO NORDISK INC. and NOVO
NORDISK A/S,

Plaintiffs,

v.

VIATRIS INC. and
MYLAN PHARMACEUTICALS INC.,

Defendant.

C.A. No. 1:23-cv-13

JOINT MOTION FOR EXTENSION

Plaintiffs, Novo Nordisk Inc. and Novo Nordisk A/S, and Defendants, Viatriis Inc. and Mylan Pharmaceuticals Inc., by their undersigned counsel, hereby move the Court for extension of the deadlines for the Initial Planning Meeting which under the Court's First Order and Notice Regarding Discovery and Scheduling dated April 3, 2023 (Dkt. No. 27) is currently due by May 3, 2023, and the day by which the parties must submit their Joint Report of Initial Planning Meeting, which is currently due May 17, 2023.

The parties respectfully and jointly request that the Court extend the deadline for the Initial Planning Meeting through and until May 17, 2023, and the deadline to submit the Joint Report of Initial Planning Meeting through and until May 31, 2023. The parties represent that the additional time will permit counsel to further confer with their clients and with each other, allowing for a Joint Report with as few areas of disagreement as possible.

Dated: May 3, 2023
Respectfully submitted,

SCHRADER COMPANION DUFF & LAW,
PLLC

/s/ James F. Companion

James F. Companion (#790)
Sandra K. Law (#6071)
401 Main Street
Wheeling, WV 26003
(304) 233-3390
jfc@schraderlaw.com
skl@schraderlaw.com

*Attorneys for Plaintiffs, Novo Nordisk Inc
and Novo Nordisk A/S*

PERKINS COIE LLP

/s/ Brandon M. White

Brandon M. White (WV Bar No. 14021)
BMWhite@perkinscoie.com
PERKINS COIE LLP
700 13th Street, NW, Suite 800
Washington, DC 20005
(202) 654-6200
bmwhite@perkincoie.com

*Attorney for Defendants, Viatris Inc. and Mylan
Pharmaceuticals Inc.*